Results 31 to 40 of about 56,983 (273)

From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution

Dermatology Research and Practice, 2018
Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods.
Giuggioli Dilia, Colaci Michele, Cocchiara Emanuele, Spinella Amelia, Lumetti Federica, Ferri Clodoveo   +5 more
doaj   +1 more source

Exploring Sources of Emotional Distress among People Living with Scleroderma: A Focus Group Study. [PDF]

PLoS ONE, 2016
BACKGROUND:Systemic sclerosis, or scleroderma, is a chronic and rare connective tissue disease with negative physical and psychological implications. Sources of emotional distress and the impact they have on the lives of people with scleroderma are not ...
Stephanie T Gumuchian, Sandra Peláez, Vanessa C Delisle, Marie-Eve Carrier, Lisa R Jewett, Ghassan El-Baalbaki, Catherine Fortune, Marie Hudson, Ann Impens, Annett Körner, Jennifer Persmann, Linda Kwakkenbos, Susan J Bartlett, Brett D Thombs   +13 more
doaj   +1 more source

Immunopathogenesis of Pediatric Localized Scleroderma

Frontiers in Immunology, 2019
Localized scleroderma (LS) is a complex disease characterized by a mixture of inflammation and fibrosis of the skin that, especially in the pediatric population, also affects extracutaneous tissues ranging from muscle to the central nervous system ...
K. Torok, Suzanne C. Li, Heidi Jacobe, S. Taber, A. Stevens, F. Zulian, T. Lu   +6 more
semanticscholar   +1 more source

Correction to "Multifactorial Induction of a "Scleroderma-Like Pattern" Without Underlying Connective Tissue Disease: Diagnostic and Therapeutic Implications". [PDF]

ACR Open Rheumatol
ACR Open Rheumatology, Volume 7, Issue 4, April 2025.
europepmc   +2 more sources

Screening and characterization of myositis‐related autoantibodies in COVID‐19 patients

Clinical and Translational Science, Volume 16, Issue 1, Page 140-150, January 2023., 2023
Abstract An efficient host immune response against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2, COVID‐19) appears to be crucial for controlling and resolving this viral infection. However, many studies have reported autoimmune characteristics in severe COVID‐19 patients.
Kai‐Fa Teo, Der‐Yuan Chen, Jeh‐Ting Hsu, Yi‐Hua Lai, Ching‐Kun Chang, Po‐Ren Hsueh, Joung‐Liang Lan, Jye‐Lin Hsu   +7 more
wiley   +1 more source

Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study

Arthritis Research & Therapy, 2017
Background Prokinetics are used to treat enteric dismotility symptoms in systemic sclerosis (SSc) patients, but they often lack adequate efficacy. The most effective prokinetics belonging to the serotonin (5-HT4) receptor agonists class were withdrawn ...
Barbara Vigone, Monica Caronni, Adriana Severino, Chiara Bellocchi, Anna Rita Baldassarri, Mirella Fraquelli, Gaia Montanelli, Alessandro Santaniello, Lorenzo Beretta   +8 more
doaj   +1 more source

BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance

Science Advances, 2018
IL-6–producing effector B cells play a pathogenic role, while IL-10–producing regulatory B cells play a protective role in a scleroderma model. Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis.
T. Matsushita, Tadahiro Kobayashi, K. Mizumaki, M. Kano, Tomoyo Sawada, Momoko Tennichi, A. Okamura, Y. Hamaguchi, Y. Iwakura, M. Hasegawa, M. Fujimoto, K. Takehara   +11 more
semanticscholar   +1 more source

Phototherapy in Scleroderma [PDF]

Dermatology and Therapy, 2016
Systemic and localized scleroderma are difficult to manage diseases with no accepted gold standard of therapy to date. Phototherapeutic modalities for scleroderma show promise. A PubMed search of information on phototherapy for scleroderma was conducted. The information was classified into effects on pathogenesis and clinical outcomes.
John Hassani, Steven R. Feldman
openaire   +2 more sources

European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Journal of the European Academy of Dermatology and Venereology, 2017
The term ‘sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement ...
R. Knobler, P. Moinzadeh, N. Hunzelmann, A. Kreuter, A. Cozzio, L. Mouthon, M. Cutolo, F. Rongioletti, C. Denton, L. Rudnicka, L. A. Frasin, V. Smith, A. Gabrielli, E. Aberer, M. Bagot, G. Bali, J. Bouaziz, A. Olesen, I. Foeldvari, C. Francès, A. Jalili, U. Just, V. Kähäri, S. Kárpáti, K. Kofoed, D. Krasowska, M. Olszewska, C. Orteu, J. Panelius, Andrea Parodi, A. Petit, P. Quaglino, A. Ranki, J. M. Schmidt, J. Seneschal, A. Skrok, M. Sticherling, C. Sunderkötter, Alain Taïeb, A. Tanew, P. Wolf, M. Worm, N. Wutte, T. Krieg   +43 more
semanticscholar   +1 more source

Scleroderma with crescentic glomerulonephritis: a case report

Journal of Medical Case Reports, 2008
Introduction Systemic sclerosis or scleroderma is an autoimmune rheumatic disease characterized by organ-based fibrosis. Renal involvement in scleroderma occurs mainly in the form of scleroderma renal crisis, affecting 5 to 10% of patients.
Ramaswami Arunachalam, Kandaswamy Thiraviam, Rajendran Tholappan, Jeyakrishnan Kizhake, Aung Hla, Iqbal Mohammaed, Jacob Chakko K, Zinna Haji, Kafeel Gazala   +8 more
doaj   +1 more source